Advancing cancer therapies. At the speed of light

Advancing cancer therapies. At the speed of light.

Hemerion® develops a unique and disruptive technology to treat glioblastoma.
A breakthrough therapy for glioblastoma patients

A breakthrough therapy for glioblastoma patients

Promising early clinical results

Promising early clinical results

A disruptive technology to tackle brain cancer and glioblastoma

News

Surgeon using Hemerion technology

Improving local control of glioblastoma: Hemerion technology presented at the 2023 Congress of the French Society of Neurosurgery

March 6, 2023

Maximilien Vermandel and Prof. Nicolas Reyns are organizing a demonstration of the Hemerion technology associated with the surgical treatment of glioblastoma during the 2023 Congress of the French Society of… ...

Read more

Prof. Costas Hadjipanayis joins Pittsburg

Prof. Costas Hadjipanayis named head of the University of Pittsburgh (UPMC) Image-Guided Neurosurgery Center

December 19, 2022

Professor Costas Hadjipanayis, a member of Hemerion's Scientific Advisory Board, has been appointed head of several neurosurgery centers at the University of Pittsburgh in the USA. An active member of… ...

Read more

Maximilien Vermandel at the inauguration of Hemerion's new premises

Hemerion continues to grow and inaugurates its new premises

October 20, 2022

Two years after its launch, Hemerion Therapeutics inaugurated its new premises on Thursday, October 20. Located in Villeneuve d’Ascq in the North of France, Hemerion Headquarters houses the team in… ...

Read more

mail icon

Stay tuned to our clinical advances

Subscribe to our newsletter

They talk about us